Centogene N v (CNTG) - News Archive

Unlocking the Genetic Secrets of Neurodegenerative Diseases: CENTOGENE’s Breakthrough Studies on Parkinson s and Frontotemporal Dementia In an era where precision medicine is transforming the landscape of healthcare, th...

Critical Path Institute (C-Path) and Centogene N.V. (CNTG) have recently signed a Memorandum of Understanding (MOU) to enhance collaboration in the field of lysosomal diseases (LDs). The partnership aims to accelerate d...

recently reported on CENTOGENE s expanding relationship with Lifera, a biopharma company owned by the PIF. This news comes as CENTOGENE N.V. recorded a cumulative net loss of $-36 million during the 12 months ending in...

Centogene N.V. (NASDAQ: CNTG), a pioneering figure offering data-driven solutions in rare and neurodegenerative diseases, in partnership with Evotec SE (Frankfurt Stock Exchange: EVT; MDAX/TecDAX; NASDAQ: EVO; ISIN: DE0...

Centogene, a global leader in genetic diagnostics, has made groundbreaking strides in revolutionizing the diagnosis and understanding of rare and neurodegenerative diseases. With their biodatabank incorporating disease...

In a groundbreaking collaboration, Centogene N.V. and Takeda have pledged to enhance their strategic partnership to provide crucial genetic testing for patients battling Lysosomal Storage Disorders (LSDs). This partners...

In a recent press release, a prominent company has announced the receipt of a delisting notice, sparking concerns among investors and market participants. The market is closely watching the development with bated breath...

In a significant development, Centogene N.V., a leading provider of data-driven solutions in rare and neurodegenerative diseases, has recently announced its decision to explore various strategic alternatives aimed at de...

In the world of rare diseases, where finding effective treatments is often a challenging and time-consuming endeavor, a recent collaboration between CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases...

CENTOGENE, a leading global provider of diagnostic and research solutions in rare diseases, has announced its successful accreditation for the French Research Tax Credit. This achievement allows CENTOGENE s partners to...

Parkinson s Disease (PD) is a chronic neurological disorder that affects millions of people worldwide, causing tremors, stiffness, and difficulties in motor function. Despite extensive research, the exact causes of PD s...

Centogene N.V., a prominent life science company specializing in data-driven solutions for rare and neurodegenerative diseases, has recently released its preliminary unaudited revenue figures for the full year of 2023....

CENTOGENE N.V., the data-driven powerhouse endeavoring to decode rare and neurodegenerative diseases, today revealed that it has successfully reached its first recruitment and genetic testing milestone in the EFRONT Stu...